PMID- 38150810
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240427
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 332
DP  - 2024 Feb
TI  - Effectiveness and safety of second-generation antipsychotics for psychiatric 
      disorders apart from schizophrenia: A systematic review and meta-analysis.
PG  - 115637
LID - S0165-1781(23)00587-5 [pii]
LID - 10.1016/j.psychres.2023.115637 [doi]
AB  - Second-generation antipsychotics (SGAs) are widely used in treating schizophrenia 
      and related disorders, also other mental disorders. However, the efficacy and 
      safety of SGAs for treating other mental disorders is unclear. A systematic 
      literature search for randomized, placebo-controlled trials of 11 SGAs for 
      treating 18 mental disorders apart from schizophrenia were carried out from 
      database inception to April 3, 2022. The primary outcome was the mean change in 
      the total score for different mental disorders. The secondary outcome was the 
      odds ratio (OR) of response, remission rates and risk ratio (RR) of adverse 
      events (AEs). A total of 181 studies (N = 65,480) were included. All SGAs showed 
      significant effects in treating other mental disorders compared with placebo, 
      except autistic disorder and dementia. Aripiprazole is the most effective 
      treatment for bipolar mania [effect size = -0.90, 95% CI: -1.59, -0.21] and 
      Tourette's disorder [effect size = -0.80, 95% CI: -1.14, -0.45], olanzapine for 
      bipolar depression [effect size = -0.86, 95% CI: -1.32, -0.39] and post-traumatic 
      stress disorder [effect size = -0.98, 95% CI: -1.55, -0.41], lurasidone for 
      depression [effect size = -0.66, 95% CI: -0.82, -0.50], quetiapine for anxiety 
      [effect size = -1.20, 95% CI: -1.96, -0.43], sleep disorders [effect size = -1.2, 
      95% CI: -1.97, -0.58], and delirium [effect size = -0.36, 95% CI: -0.70, -0.03], 
      and risperidone for obsessive-compulsive disorder [effect size = -2.37, 95% CI: 
      -3.25, -1.49], respectively. For safety, AE items for each SGAs was different. 
      Interestingly, we found that some AEs of OLZ, QTP, RIS and PALI have significant 
      palliative effects on some symptoms. Significant differences in the efficacy and 
      safety of different SGAs for treatment of other mental disorders should be 
      considered for choosing the drug and for the balance between efficacy and 
      tolerability for the specific patient.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Feng, Xue-Zhu
AU  - Feng XZ
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China; Department of Neurobiology, Peking University Health 
      Science Center, Beijing 100191, China.
FAU - Li, Zhe
AU  - Li Z
AD  - School of Social Development and Public Policy (SSDPP), Beijing Normal 
      University, Beijing 100875, China.
FAU - Li, Zi-Yi
AU  - Li ZY
AD  - Department of Endocrinology, Key Laboratory of Endocrinology of National Health 
      Commission, Translation Medicine Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
      100005, China.
FAU - Wang, Ke
AU  - Wang K
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China.
FAU - Tan, Xuan
AU  - Tan X
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China; Department of Neurobiology, Peking University Health 
      Science Center, Beijing 100191, China.
FAU - Zhao, Yu-Yu
AU  - Zhao YY
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China; Department of Neurobiology, Peking University Health 
      Science Center, Beijing 100191, China.
FAU - Mi, Wei-Feng
AU  - Mi WF
AD  - Peking University Sixth Hospital, Peking University Institute of Mental Health, 
      NHC Key Laboratory of Mental Health (Peking University), National Clinical 
      Research Centre for Mental Disorders (Peking University Sixth Hospital), Peking 
      University, Beijing, China.
FAU - Zhu, Wei-Li
AU  - Zhu WL
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China.
FAU - Bao, Yan-Ping
AU  - Bao YP
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China.
FAU - Lu, Lin
AU  - Lu L
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China; Peking University Sixth Hospital, Peking University 
      Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking 
      University), National Clinical Research Centre for Mental Disorders (Peking 
      University Sixth Hospital), Peking University, Beijing, China; Peking-Tsinghua 
      Centre for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, 
      Peking University, Beijing, China; Research Unit of Diagnosis and Treatment of 
      Mood Cognitive Disorder, Chinese Academy of Medical Sciences (No.2018RU006), 
      Beijing, China.. Electronic address: linlu@bjmu.edu.cn.
FAU - Li, Su-Xia
AU  - Li SX
AD  - National Institute on Drug Dependence and Beijing Key laboratory of Drug 
      Dependence Research, Peking University, 38 Xue Yuan Road, Haidian District, 
      Beijing 100191, China. Electronic address: li313@bjmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231202
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Antipsychotic Agents)
RN  - N7U69T4SZR (Olanzapine)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Humans
MH  - *Antipsychotic Agents/adverse effects/therapeutic use
MH  - Olanzapine/adverse effects/therapeutic use
MH  - Quetiapine Fumarate/adverse effects/therapeutic use
MH  - Risperidone/adverse effects/therapeutic use
MH  - *Schizophrenia/drug therapy
OTO - NOTNLM
OT  - Meta-analysis
OT  - Placebo
OT  - Randomized controlled trials
OT  - Second-generation antipsychotics
COIS- Declaration of Competing Interest The author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/12/28 00:42
MHDA- 2024/01/22 06:42
CRDT- 2023/12/27 18:03
PHST- 2023/08/10 00:00 [received]
PHST- 2023/11/21 00:00 [revised]
PHST- 2023/11/25 00:00 [accepted]
PHST- 2024/01/22 06:42 [medline]
PHST- 2023/12/28 00:42 [pubmed]
PHST- 2023/12/27 18:03 [entrez]
AID - S0165-1781(23)00587-5 [pii]
AID - 10.1016/j.psychres.2023.115637 [doi]
PST - ppublish
SO  - Psychiatry Res. 2024 Feb;332:115637. doi: 10.1016/j.psychres.2023.115637. Epub 
      2023 Dec 2.